Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. They focus on delivering biologics and drugs orally. Recently, they announced a new research agreement with Chugai Pharmaceutical Co., Ltd. The agreement, signed on August 13, 2024, includes two molecules. The targets of these molecules are not disclosed and are provided by Chugai.
A thorough analysis showed that Rani’s RaniPill® technology had bioavailability similar to subcutaneous delivery for both studied molecules.
“We are excited to work with Chugai, a top global player known for its research skills and focus on patient-centered innovation,” said Talat Imran, CEO of Rani Therapeutics. Chugai’s tech-focused drug discovery fits well with Rani’s goal. Rani aims to make it easier to deliver antibodies, peptides, and large proteins orally. We have evaluated 19 molecules in preclinical studies. We also completed three Phase 1 clinical trials with the RaniPill® capsule. This shows its versatility with many biologics.”
Also Read: Rakuten Healthcare Launch Online Med Advice & Delivery
Tom Igawa, PhD, Head of Research at Chugai, said, “At Chugai, we focus on new drug discovery. Our approach is rooted in science.” We are excited to assess Rani’s new technology. It offers a fresh and promising way to add value to many therapy programs.”
